Adalimumab Treats Hidradenitis Suppurativa But Has Multisystem Adverse Event Profile
The effects of adalimumab on HS-PGA and DLQI scores of patients with HS who had been treated at least 6 months were evaluated.
The effects of adalimumab on HS-PGA and DLQI scores of patients with HS who had been treated at least 6 months were evaluated.
The dermatologic aspects of COVID-19 infection are reviewed and identify the skin complications seen and preventative measures that can be taken.
Concomitant treatment of common comorbidities of HS, including anxiety and depression, metabolic syndrome, and smoking, may improve treatment outcomes.
Valerie Harvey, MD and Lynn McKinley-Grant, MD explain the importance of diversity and specialized training to treat patients with skin of color in the field of dermatology.
The prevalence and characteristics of hidradenitits suppurative-related pain in patients was assessed in a large study.
A possible bidirectional association between HS and AD was evaluated.
Baseline BMI and change in BMI of patients with HS and control patients before and after diagnosis of HS were compared.
A machine learning-based mobile phone app may serve as a diagnostic support tool for a range of common skin conditions in patients of color.
The long-term efficacy, safety, and effect on quality of life of adalimumab in treating patients with hidradenitis suppurativa is reported.
A roundtable discussion by experts in issues facing patients with skin of color reveals interesting insights.